JCA Pulse › JCA discontinued
JCA discontinuedCatequentinib: EU joint clinical assessment
Synovial sarcoma or leiomyosarcoma
This assessment was discontinued.
Overview
- Company
- Advenchen Laboratories
- Therapy area
- Solid tumours · Sarcoma
- Indication
- Synovial sarcoma or leiomyosarcoma
- EMA validation
- 17 Jul 2025
- Discontinued
- 22 Jun 2026
- JCA assessor
- TLV, Sweden
- Co-assessor
- NoMA, Norway
- Regulatory status
- Negative CHMP opinion (Jul 2026); re-examination requested.
- Reason
- The JCA dossier did not meet the requirements of Article 9(2)–(4) of the HTA Regulation.
Sources
Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.
From Evidaxia
- EU JCA dossiers and PICO scopingSupport from PICO scoping to the dossier
- JCA PICO scoping: process and preparationHow assessors set the scope
- EU JCA timelineEvery upcoming milestone
Also in Solid tumours
- Bifikafusp alfa / onfekafusp alfa (Nidlegy)Melanoma, neoadjuvant
- CamizestrantHR+/HER2− breast cancer, ESR1 switch
- CosibelimabCutaneous squamous cell carcinoma
- DaraxonrasibMetastatic pancreatic cancer
- Ensartinib (Gevalka)ALK-positive NSCLC
- FuzuloparibmCRPC, first line